InMed Pharmaceuticals (INM) Share-based Compensation Growth (3y) (2022 - 2026)
InMed Pharmaceuticals (INM) Share-based Compensation Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn | 10.06% |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn | 9.14% |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn | 0.43% |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -8.13% |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | -1.73% |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn | -8.04% |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | InMed Pharmaceuticals | 6.56 Mn | 1.32 Mn | - | -8.35% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29.49% |
| Dec 31, 2025 | -33.09% |
| Sep 30, 2025 | -29.53% |
| Jun 30, 2025 | -33.13% |
| Mar 31, 2025 | -30.20% |
| Dec 31, 2024 | -28.22% |
| Sep 30, 2024 | -31.24% |
| Jun 30, 2024 | -43.92% |
| Mar 31, 2024 | -35.62% |
| Dec 31, 2023 | -42.61% |
| Sep 30, 2023 | -33.43% |
| Jun 30, 2023 | -66.89% |
| Mar 31, 2023 | -37.26% |
| Dec 31, 2022 | -37.11% |
| Sep 30, 2022 | -30.69% |